Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Conditions

• Obesity

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Ribupatide — DRUG
  SC Injection
• Placebo — DRUG
  SC Injection

Study Details

The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

Key Dates

Start date

Mar 4, 2026

Status verified

May 2026

Primary completion

May 31, 2027

Completion

Jun 30, 2027

Study Design

Enrollment

250 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Ribupatide: Dose 1
  Participants will receive Dose 1 of ribupatide once weekly.
• Experimental: Ribupatide: Dose 2
  Participants will receive Dose 2 of ribupatide once weekly.
• Experimental: Ribupatide: Dose 3
  Participants will receive Dose 3 of ribupatide once weekly.
• Experimental: Ribupatide: Dose 4
  Participants will receive Dose 4 of ribupatide once weekly.
• Placebo Comparator: Placebo
  Participants will receive placebo matched to ribupatide once weekly.

Primary Outcome Measure

Percent Change From Baseline in Body Weight at Week 48 [ Time Frame: Baseline, Week 48 ]

Locations (35)

Find similar trials in Mesa, AZ

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Physical and Behavioral Traits of Overweight and Obese Adults
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
  PHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
• Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
  Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia